和黄医药索乐匹尼布：III期研究结果发表于《柳叶刀·血液病学》，国家药监局纳入突破性治疗品种

和讯网06-17

快讯正文【和黄医药宣布其新型药物索乐匹尼布的III期研究结果在《柳叶刀·血液病学》发表】和黄医药近日宣布，其研发的口服抑制剂索乐匹尼布在治疗成人原发免疫性血小板减少症的III期研究ESLIM-01结果已在《柳叶刀·血液病学》上公布。该药物是一种高选择性的脾酪氨酸激酶(Syk)抑制剂，针对血液恶性肿瘤和免疫性疾病。免疫性血小板减少症是一种自身免疫性出血性疾病，影响患者的生活质量。研究结果显示，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2444183598?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-17 09:44","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2444183598","market":"us","top_or_hot":-1,"title":"和黄医药索乐匹尼布：III期研究结果发表于《柳叶刀·血液病学》，国家药监局纳入突破性治疗品种","media":"和讯网","content":"<div>\n<p>快讯正文【和黄医药宣布其新型药物索乐匹尼布的III期研究结果在《柳叶刀·血液病学》发表】和黄医药近日宣布，其研发的口服抑制剂索乐匹尼布在治疗成人原发免疫性血小板减少症的III期研究ESLIM-01结果已在《柳叶刀·血液病学》上公布。该药物是一种高选择性的脾酪氨酸激酶(Syk)抑制剂，针对血液恶性肿瘤和免疫性疾病。免疫性血小板减少症是一种自身免疫性出血性疾病，影响患者的生活质量。研究结果显示，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061709453695b7c8c5&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和黄医药索乐匹尼布：III期研究结果发表于《柳叶刀·血液病学》，国家药监局纳入突破性治疗品种</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黄医药索乐匹尼布：III期研究结果发表于《柳叶刀·血液病学》，国家药监局纳入突破性治疗品种\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-17 09:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061709453695b7c8c5&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>快讯正文【和黄医药宣布其新型药物索乐匹尼布的III期研究结果在《柳叶刀·血液病学》发表】和黄医药近日宣布，其研发的口服抑制剂索乐匹尼布在治疗成人原发免疫性血小板减少症的III期研究ESLIM-01结果已在《柳叶刀·血液病学》上公布。该药物是一种高选择性的脾酪氨酸激酶(Syk)抑制剂，针对血液恶性肿瘤和免疫性疾病。免疫性血小板减少症是一种自身免疫性出血性疾病，影响患者的生活质量。研究结果显示，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061709453695b7c8c5&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HCM","symbol_name":"和黄医药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061709453695b7c8c5&s=b","article_id":"2444183598","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061709453695b7c8c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2444183598","pubTimestamp":1718588644,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"快讯正文和黄医药近日宣布，其研发的口服抑制剂索乐匹尼布在治疗成人原发免疫性血小板减少症的III期研究ESLIM-01结果已在《柳叶刀·血液病学》上公布。研究结果显示，索乐匹尼布可能成为已接受至少一种治疗的患者的有效治疗选择。中国国家药品监督管理局已将索乐匹尼布纳入突破性治疗品种，并于2024年1月受理其新药上市申请，同时纳入优先审评。和黄医药保留了索乐匹尼布在全球的所有权利。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HCM":"和黄医药","BK4531":"中概回港概念","BK4134":"信息科技咨询与其它服务","00013":"和黄医药","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4007":"制药","III":"信息服务"},"translate_title":"Chi-Med Solapinib: Phase III study results published in \"The Lancet Hematology\", included in breakthrough therapy by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":1,"III":1,"00013":0.9},"content_text":"快讯正文【和黄医药宣布其新型药物索乐匹尼布的III期研究结果在《柳叶刀·血液病学》发表】和黄医药近日宣布，其研发的口服抑制剂索乐匹尼布在治疗成人原发免疫性血小板减少症的III期研究ESLIM-01结果已在《柳叶刀·血液病学》上公布。该药物是一种高选择性的脾酪氨酸激酶(Syk)抑制剂，针对血液恶性肿瘤和免疫性疾病。免疫性血小板减少症是一种自身免疫性出血性疾病，影响患者的生活质量。研究结果显示，索乐匹尼布可能成为已接受至少一种治疗的患者的有效治疗选择。中国国家药品监督管理局已将索乐匹尼布纳入突破性治疗品种，并于2024年1月受理其新药上市申请，同时纳入优先审评。此外，和黄医药计划在美国开展剂量探索研究，并已在中国启动用于治疗温抗体型自身免疫性溶血性贫血的II/III期研究。和黄医药保留了索乐匹尼布在全球的所有权利。下载和讯APP查看快讯，体验更佳>>","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444183598"}